143 related articles for article (PubMed ID: 12393743)
1. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor.
Waddington SN; Buckley SM; Nivsarkar M; Jezzard S; Schneider H; Dahse T; Kemball-Cook G; Miah M; Tucker N; Dallman MJ; Themis M; Coutelle C
Blood; 2003 Feb; 101(4):1359-66. PubMed ID: 12393743
[TBL] [Abstract][Full Text] [Related]
2. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep.
David AL; McIntosh J; Peebles DM; Cook T; Waddington S; Weisz B; Wigley V; Abi-Nader K; Boyd M; Davidoff AM; Nathwani AC
Hum Gene Ther; 2011 Apr; 22(4):419-26. PubMed ID: 20919876
[TBL] [Abstract][Full Text] [Related]
4. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
5. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs.
Zhang J; Xu L; Haskins ME; Parker Ponder K
Blood; 2004 Jan; 103(1):143-51. PubMed ID: 12969967
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.
Ge Y; Powell S; Van Roey M; McArthur JG
Blood; 2001 Jun; 97(12):3733-7. PubMed ID: 11389010
[TBL] [Abstract][Full Text] [Related]
7. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.
Chen XG; Zhu HZ; Gong JL; Li F; Xue JL
Acta Pharmacol Sin; 2004 Jun; 25(6):789-93. PubMed ID: 15169633
[TBL] [Abstract][Full Text] [Related]
8. Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.
Nivsarkar MS; Buckley SM; Parker AL; Perocheau D; McKay TR; Rahim AA; Howe SJ; Waddington SN
J Immunol Res; 2015; 2015():397879. PubMed ID: 25759840
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-guided percutaneous delivery of adenoviral vectors encoding the beta-galactosidase and human factor IX genes to early gestation fetal sheep in utero.
David A; Cook T; Waddington S; Peebles D; Nivsarkar M; Knapton H; Miah M; Dahse T; Noakes D; Schneider H; Rodeck C; Coutelle C; Themis M
Hum Gene Ther; 2003 Mar; 14(4):353-64. PubMed ID: 12659676
[TBL] [Abstract][Full Text] [Related]
10. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
Miao CH; Thompson AR; Loeb K; Ye X
Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
[TBL] [Abstract][Full Text] [Related]
11. Regulation of human factor IX expression using doxycycline-inducible gene expression system.
Srour MA; Fechner H; Wang X; Siemetzki U; Albert T; Oldenburg J; Hanfland P; Poller W; Brackmann HH; Schwaab R
Thromb Haemost; 2003 Sep; 90(3):398-405. PubMed ID: 12958607
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression.
Michou AI; Santoro L; Christ M; Julliard V; Pavirani A; Mehtali M
Gene Ther; 1997 May; 4(5):473-82. PubMed ID: 9274725
[TBL] [Abstract][Full Text] [Related]
13. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.
Wang JM; Zheng H; Sugahara Y; Tan J; Yao SN; Olson E; Kurachi K
Hum Gene Ther; 1996 Sep; 7(14):1743-56. PubMed ID: 8886845
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
15. Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
Sabatino DE; Mackenzie TC; Peranteau W; Edmonson S; Campagnoli C; Liu YL; Flake AW; High KA
Mol Ther; 2007 Sep; 15(9):1677-85. PubMed ID: 17565352
[TBL] [Abstract][Full Text] [Related]
16. Highly sensitive and species-specific assay for quantification of human transgene expression levels.
Haack A; Poller W; Schneider-Rasp S; Thalheimer P; Schmitt C; Hanfland P; Brackmann HH; Schwaab R
Haemophilia; 1999 Sep; 5(5):334-9. PubMed ID: 10583515
[TBL] [Abstract][Full Text] [Related]
17. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.
Nathwani AC; Davidoff AM; Hanawa H; Hu Y; Hoffer FA; Nikanorov A; Slaughter C; Ng CY; Zhou J; Lozier JN; Mandrell TD; Vanin EF; Nienhuis AW
Blood; 2002 Sep; 100(5):1662-9. PubMed ID: 12176886
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
[TBL] [Abstract][Full Text] [Related]
20. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
